PRTA
HEALTHCAREProthena Corporation plc
$11.18-0.01 (-0.09%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PRTA Today?
No stock-specific AI insight has been generated for PRTA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.32$11.69
$11.18
Fundamentals
Market Cap$566M
P/E Ratio—
EPS$-4.53
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume334K
Avg Volume (10D)—
Shares Outstanding53.8M
PRTA News
20 articles- Prothena Posts Q1 Earnings as Revenues Surge on Milestone PaymentYahoo Finance·May 8, 2026
- Prothena Reports First Quarter 2026 Financial Results and Business HighlightsPharmiWeb.com·May 8, 2026
- Prothena to Report First Quarter 2026 Financial Results on May 7Yahoo Finance·Apr 30, 2026
- Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition AnnouncementMotley Fool·Apr 29, 2026
- 3 Growth Companies Insiders Are Eager To HoldYahoo Finance·Apr 29, 2026
- Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyYahoo Finance·Apr 27, 2026
- Prothena Announces Leadership Team UpdatesYahoo Finance·Apr 10, 2026
- AZN Posts Data From Hypophosphatasia Program on Efzimfotase AlfaYahoo Finance·Apr 1, 2026
- Top Growth Companies With High Insider Ownership In March 2026Yahoo Finance·Mar 31, 2026
- Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host DiseaseYahoo Finance·Mar 31, 2026
- RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseYahoo Finance·Mar 30, 2026
- Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?Yahoo Finance·Mar 27, 2026
- Why Is Jazz (JAZZ) Down 3.9% Since Last Earnings Report?Yahoo Finance·Mar 26, 2026
- Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a BetYahoo Finance·Mar 26, 2026
- Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026Yahoo Finance·Mar 21, 2026
- Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with CardiomyopathyYahoo Finance·Mar 9, 2026
- Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to TradeYahoo Finance·Mar 3, 2026
- Prothena Announces up to $100 Million Share Repurchase PlanYahoo Finance·Feb 27, 2026
- Prothena Q4 Earnings Meet Estimates, Pipeline Progress in FocusYahoo Finance·Feb 20, 2026
- Prothena Corporation plc Q4 2025 Earnings Call SummaryMoby·Feb 20, 2026
All 20 articles loaded
Price Data
Open$11.19
Previous Close$11.19
Day High$11.30
Day Low$11.02
52 Week High$11.69
52 Week Low$4.32
52-Week Range
$4.32$11.69
$11.18
Fundamentals
Market Cap$566M
P/E Ratio—
EPS$-4.53
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume334K
Avg Volume (10D)—
Shares Outstanding53.8M
About Prothena Corporation plc
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—